February 2019 | DelveInsight Business Research Skip to main content
delveinsight blog
  • ABOUT
    • About Us
    • Our Leadership
    • Our Clients
  • CAPABILITIES & SOLUTIONS
    • Reports
    • Competitive Intelligence
    • Case Study
  • CONSULTING SERVICE
  • REPORT STORE
  • MEDIA
    • Blog
    • Press Releases
    • White Papers / Newsletter
    • Events
  • CAREER
  • CONTACT US
  • Report Store
Healthcare blog

Month: February 2019

Feb 28 Rare Disease Day

Rare Disease Day

Feb 28, 2019Feb 28, 2019 DelveInsight Leave a comment
Read More
Feb 28 The Business Cocktail

The Business Cocktail

Feb 28, 2019Feb 28, 2019 DelveInsight Leave a comment

Cell Medica receives funds for its cell therapy A USD 8.7 million grant to Cell Medica has been given by Cancer Prevention and Research Institute of…

Read More
Feb 27 A helping hand in treatment of CRC

A helping hand in treatment of CRC

Feb 27, 2019Feb 27, 2019 DelveInsight Leave a comment

Patients suffering from Colorectal Cancer (CRC) usually gets affected with distant organ metastases spreading the tumor to other parts of the body. Patients with unresectable or…

Read More
Feb 26 Notizia

Notizia

Feb 26, 2019Feb 26, 2019 DelveInsight Leave a comment

 Vertex, CRISPR Therapeutics treated a patient using CRISPR In the very first, a patient diagnosed with Beta thalassemia was treated using CRISPRgene editing tool by Vertex…

Read More
Feb 25 A CRISPR WAY TO USE STEM CELLS

A CRISPR WAY TO USE STEM CELLS

Feb 25, 2019Feb 26, 2019 DelveInsight Leave a comment

Stem Cells therapies and CRISPR gene-editing are not new. Having able to grow the desired cells and manipulate the genome system have proved to be the…

Read More
Feb 22 What is Cholangiocarcinoma (CCA)?

What is Cholangiocarcinoma (CCA)?

Feb 22, 2019Feb 22, 2019 DelveInsight Leave a comment

Cholangiocarcinoma (BILE Duct cancer) is a type of uncommon CANCER. It arises in Bile ducts. The Bile duct is a long tubule like structure which connects…

Read More
Feb 21 The Business Cocktail

The Business Cocktail

Feb 21, 2019Feb 21, 2019 DelveInsight Leave a comment

Peloton Therapeutics raises USD 150 Million for treating Advance Kidney Cancer Peloton Therapeutics has been in the process of developing small molecule drugs to treat Cancer, has…

Read More
Feb 20 CRISPR proves to be a blessing for LASSA  fever

CRISPR proves to be a blessing for LASSA fever

Feb 20, 2019Feb 21, 2019 DelveInsight Leave a comment

The ability of CRISPR to change an organism’s DNA has lead researchers, particularly from Nigeria to use the tool to perform diagnostic tests. Since CRISPR therapeutics…

Read More
Feb 19 Notizia

Notizia

Feb 19, 2019Feb 19, 2019 DelveInsight Leave a comment

CRISPR treatment delivers benefits in mice The researchers from Duke University along with drugmaker Sarepta Therapeutics published a report stating that a single change in the…

Read More
Feb 18 Human cells reprogrammed to create insulin in diabetic mice

Human cells reprogrammed to create insulin in diabetic mice

Feb 18, 2019Feb 18, 2019 DelveInsight Leave a comment

Diabetes – a chronic condition in which sugar is not processed in the body. Diabetic people either do not produce enough insulin or cells halt responding…

Read More

Posts navigation

1 2 Older posts

Recent Posts

  • Fragile X Syndrome Market
  • Omega’s sixth funding round; Correvio’s drug failure; and BIMA acquisition
  • Gaucher disease Market: Pipeline and Future Trends
  • Acquisition of ArQule; Synthorx; and Zentalis nabs a raise
  • Are Rare diseases truly Rare?

Browse by Category

  • Anti-coagulants (8)
  • API Business Opportunity (5)
  • Articles (285)
  • Atrial Fibrillation (6)
  • Business Consultant (449)
    • Pharma Consultant (430)
  • Chimeric Antigen Receptor (CAR) T-cell Therapy (7)
  • CNS Indications (1)
  • CVS Indications (4)
  • DelveInsight's Drug Report (154)
  • DelveInsight's Indication Pipeline Reports (69)
  • DelveInsight's Oncology based Reports (47)
  • Gene Therapy Products (31)
  • Infographics (40)
  • new therapeutic target (5)
  • Newsletter (2)
  • Notizia (156)
  • Oncology based Indications (11)
  • Orphan market (5)
  • PD-1 and PD-L1 inhibitors (5)
  • Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors (1)
  • Pulmonary arterial hypertension (1)
  • Rising of Orphan Drug Development (3)
  • Snippets (128)
  • Specialized Reports (15)
  • The Business Cocktail (140)
  • Uncategorized (61)
  • Venous Thromboembolism (3)

Archives

  • December 2019 (12)
  • November 2019 (24)
  • October 2019 (27)
  • September 2019 (23)
  • August 2019 (22)
  • July 2019 (25)
  • June 2019 (30)
  • May 2019 (29)
  • April 2019 (29)
  • March 2019 (27)
  • February 2019 (20)
  • January 2019 (18)
  • December 2018 (19)
  • November 2018 (26)
  • October 2018 (21)
  • September 2018 (20)
  • August 2018 (26)
  • July 2018 (13)
  • June 2018 (5)
  • May 2018 (8)
  • April 2018 (6)
  • March 2018 (14)
  • February 2018 (11)
  • January 2018 (15)
  • December 2017 (8)
  • November 2017 (13)
  • October 2017 (8)
  • September 2017 (14)
  • August 2017 (13)
  • July 2017 (9)
  • June 2017 (14)
  • May 2017 (20)
  • April 2017 (19)
  • March 2017 (24)
  • February 2017 (21)
  • January 2017 (23)
  • December 2016 (22)
  • November 2016 (23)
  • October 2016 (17)
  • September 2016 (21)
  • August 2016 (17)
  • May 2016 (4)
  • March 2016 (8)
  • February 2016 (3)
  • January 2016 (7)
  • November 2015 (1)
  • October 2015 (1)
  • September 2015 (2)
  • August 2015 (2)
  • July 2015 (8)
  • June 2015 (4)
  • May 2015 (1)
  • April 2015 (5)
  • March 2015 (6)
  • February 2015 (2)
  • January 2015 (5)
  • December 2014 (17)
  • November 2014 (2)
  • September 2014 (1)
  • August 2014 (7)
  • July 2014 (7)
delveinsight


Quick Links

  • About
  • Capabilities & Solutions
  • Report Store
  • Media
  • Career
  • Contact Us

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Tweets by @DelveInsight

Copyright © 2019 Delveinsight.

  • Sitemap
  • Terms & Conditions
  • Privacy policy